The combination therapy of R-405 with ICIs likely neutralized these effects: anti-PD-1 could be able to counteract the increase of PD-L1 expression in LLC1-PSMA tumors and prevent the anergy of the anti-tumor T cells, while anti-CTLA-4 could increase T-cell priming against tumor antigens and/or depleting Treg population in Renca-PSMA tumors. This evidence concerns the gene FOLH1 and neoplasm.